DRL posts Q2 FY17 and H1FY17 results
In Q2 FY17, EBITDA is at Rs 6.4 billion and profit after tax at Rs 2.9 billion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Home » GV Prasad
Browsing Tag
GV Prasad
Dr Reddy’s to acquire Teva’s product portfolio for US Market
The portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA. It also comprises complex generic…
DRL posts consolidated revenues of Rs 37.6 billion, showing seven per cent growth YoY
Gross profit margin were at 61.1 per cent